Smith & Nephew plc
15 Adam Street
London,
WC2N 6LA
Phone: 44 20 7401 7646
Fax: 44 20 7930 3353
Web Site: http://www.smith-nephew.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| Smith & Nephew plc, together with its subsidiaries, engages in the development, manufacture, marketing, and sale of medical devices worldwide. The company operates through three segments: Orthopaedics, Endoscopy, and Advanced Wound Management. The Orthopaedics segment offers reconstruction implants, including hip, knee, and shoulder joints, as well as ancillary products, such as bone cement and mixing systems for use in the cemented reconstruction joint surgery. This segment also provides trauma fixation products consisting of internal and external devices and orthobiological materials for use in the stabilisation of fractures and deformity correction procedures; and clinical therapies products comprising bone growth stimulation, joint fluid therapies, and outpatient spine products. The Endoscopy segment offers surgeons endoscopic technologies for surgery, including specialised devices and fixation systems to repair damaged tissue; fluid management and insufflation equipment for surgical access; digital cameras, digital image capture, scopes, light sources, and monitors to assist with visualisation; and radiofrequency wands, electromechanical and mechanical blades, and hand instruments for resecting damaged tissue. The Advanced Wound Management segment provides initial wound bed preparation and full wound closure products. This segmentÂ’s products are targeted at chronic wounds connected with the older population, including pressure sores and venous leg ulcers, and the alleviation of wounds, such as burns and invasive surgery that impact the wider population. Smith & Nephew plc serves various providers of medical and surgical services. The company was founded in 1856 and is headquartered in London, the United Kingdom. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Mr. David Illingworth , 56
Chief Exec. Officer, Exec. Director, Chairman of Disclosures Committee, Chairman of Risk Committee and Member of Nominations Committee |
N/A
| N/A | Mr. Adrian Hennah , 50
Chief Financial Officer, Exec. Director and Member of Disclosures Committee |
$
1.62M | N/A | Mr. Jeff Adams ,
Sr. VP of Global Operations |
N/A
| N/A | Mr. Mark A. Augusti , 44
Pres Biologics & Clinical Therapies |
N/A
| N/A | Mr. Michael Frazzette , 48
Pres of Endoscopy |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
Help
Profile
Reuters offers more in-depth
